Healthcare
Shionogi & Co., Ltd.(SGIOF)
Live Price
Offline$16.00
+0.00% today
1Y Change
-9.22%
Window
Jun 20, 2025 → Jun 15, 2026
- Market Cap
- $2.66T
- Revenue Growth
- +0.7%
- EPS Growth
- +7.6%
- Dividend Yield
- 2.3%
Coverage: 247 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shionogi & Co., Ltd. (SGIOF) is a Healthcare stock with a market cap of $2.66T and listed on OTC. The stock last traded around $16.00 and down 9.2% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +0.7%, EPS growth of +7.6%, a dividend yield of 2.3%. What stands out right now is revenue +0.7%, EPS +7.6%, free cash flow +13.8% with operating margin 35.0% and ROIC 8.5%. The dividend is present but secondary, with a yield around 2.3%. Valuation is more restrained than many high-expectation growth names at P/E 13.7 and price/sales 5.7. Stock Foundry combines SGIOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.7% vs +7.6% peer median
Operating Margin
Above sector median
+35.0% vs +19.4% peer median
P/E
Below sector median
13.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +0.7% and EPS at +7.6%, with operating margin around 35.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.3%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGIOF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGIOF Max Drawdown
-38.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SGIOF and SPY.
Company Overview
Shionogi & Co., Ltd.
Other OTC
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
- Leadership
- Isao Teshirogi
- IPO Date
- Feb 28, 2018
- Employees
- 5.0k
- Street Address
- 1-8, Doshomachi 3-chome
- Mailing
- Osaka, 541-0045
- Region
- Osaka, JP
- Reporting Currency
- USD
- Investor Line
- 81 6 6202 2161
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 13.7
- EV/EBITDA
- 10.5
- Price/Sales
- 5.7
- Price/Book
- 1.8
Growth
- Revenue
- +0.7%
- EPS
- +7.6%
- Free Cash Flow
- +13.8%
Profitability
- Gross Margin
- 84.3%
- Operating Margin
- 35.0%
- Net Margin
- 41.9%
- ROE
- 13.7%
- ROIC
- 8.5%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 5.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.